Germany-based Paion AG has appointed Timothy Morris as a non-executive director and financial advisor to the company. This includes advising Paion Inc on the commercialisation of remimazolam, a prospective anaesthetic for the hospital market.
Mr Morris has spent 31 years in professional finance and accounting and as a biopharmaceutical company chief financial officer. He is currently CFO and head of business development at AcelRx Pharmaceuticals Inc which is developing therapies for the treatment of pain.
Paion announced the appointment on 7 August 2015.
Copyright 2015 Evernow Publishing Ltd